Rhythm Pharmaceuticals Awaits Pivotal Moment for Setmelanotide

On April 7, 2025, Rhythm Pharmaceuticals will disclose the topline results from its Pivotal Phase 3 TRANSCEND trial, evaluating setmelanotide in patients with acquired hypothalamic obesity. The stakes are high for the biopharmaceutical company, which has been focused on transforming the lives of patients living with rare neuroendocrine diseases. The trial's outcome could significantly impact the company's future, both in terms of market performance and its standing in the biotech industry.



The TRANSCEND trial is a global, randomized, double-blind, placebo-controlled study that enrolled 120 patients aged 4 years and older. Participants were randomized 2:1 to receive either a daily subcutaneous injection of setmelanotide or a placebo. The primary endpoint is the mean percent change in body mass index (BMI) from baseline after 52 weeks of treatment. Secondary endpoints include daily hunger, hyperphagia, weight, quality of life, and safety and tolerability.

Previous clinical trials of setmelanotide have shown promising results. A Phase 2 study published in The Lancet Diabetes & Endocrinology demonstrated that setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment. The study also showed that 89% of patients achieved a 5% or greater reduction in BMI after 16 weeks, and 78% achieved a 10% or greater reduction. These findings suggest that setmelanotide could be a game-changer for patients with acquired hypothalamic obesity, a rare form of extreme obesity that occurs following damage to the hypothalamic region of the brain.

The potential market implications for Rhythm Pharmaceuticals are significant. If the topline results from the TRANSCEND trial are positive, the company could see a surge in its stock performance. Investors often react positively to successful clinical trial outcomes, as they signal the potential for new revenue streams and market expansion. For instance, the company's fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) was $41.8 million, an increase of 26% from the third quarter of 2024. Positive results from the TRANSCEND trial could further boost these sales figures, as setmelanotide would be indicated for a broader patient population.

In the long term, positive results could solidify Rhythm Pharmaceuticals' position as a leader in the treatment of rare neuroendocrine diseases. The company has already demonstrated its commitment to this area with its lead asset, IMCIVREE®, which is approved for chronic weight management in patients with monogenic or syndromic obesity due to POMC, PCSK1, or LEPR deficiency, or Bardet-Biedl syndrome (BBS). Expanding the indication to include acquired hypothalamic obesity would further validate the company's expertise and potentially attract more investment and partnerships.

Additionally, the company's strategic partnerships and clinical development programs could benefit from positive trial results. For example, Rhythm Pharmaceuticals has completed enrollment in the Phase 2 trial of oral MC4R agonist bivamelagon in acquired hypothalamic obesity and has a strategic partnership agreement with Trispera Pharma Solutions in Turkey. Positive results from the TRANSCEND trial could enhance the value of these partnerships and accelerate the development of new therapies.

However, it is important to note that the biotech industry is fraught with uncertainty. While the Phase 2 study results are encouraging, the TRANSCEND trial results will provide further insights into the efficacy and safety of setmelanotide for treating acquired hypothalamic obesity. If the TRANSCEND trial results are consistent with the previous Phase 2 study results, it would suggest that setmelanotide has the potential to be an effective and safe treatment option for patients with acquired hypothalamic obesity. The TRANSCEND trial results will also provide additional data on the drug's safety and tolerability, which is important for understanding the potential risks and benefits of setmelanotide for this patient population.

In conclusion, the upcoming disclosure of the topline results from the Pivotal Phase 3 TRANSCEND trial is a pivotal moment for Rhythm Pharmaceuticals. The outcome could have significant market implications, potentially driving short-term stock performance and long-term growth. The company's commitment to rare neuroendocrine diseases, strategic partnerships, and clinical development programs position it well to capitalize on these results. However, investors should remain cautious, as the biotech industry is known for its volatility and uncertainty.